Cyclo(RGDyK) is widely used in biomedical research due to its ability to specifically target integrin receptors, which are overexpressed in various cancer cells and angiogenic blood vessels. It is commonly employed in the development of targeted drug delivery systems, allowing therapeutic agents to be directed precisely to tumor sites while minimizing off-target effects. Additionally, it is utilized in imaging techniques, such as PET and fluorescence imaging, to visualize and monitor tumor progression and angiogenesis. Cyclo(RGDyK) is also studied in the field of tissue engineering, where it promotes cell adhesion and integration in scaffolds designed for regenerative medicine. Its role in inhibiting integrin-mediated pathways further makes it a potential candidate for anti-cancer and anti-angiogenic therapies.